Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer is a research paper published in International Journal of Molecular Sciences (2022). On theSindex it has a DataRank of 1.9. It has been cited 102 times, with 99 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.695
From this paper's citation signal
Citation Network Contribution
1.2
From 67 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 99 citers.
Lloyd Foundation Melanoma Research Grant (CY)
Grant: NCI R01-CA116021 (AR)
Lloyd Foundation Melanoma Research Grant (CY)
Grant: NCI-R01-CA243326 (AR)
Lloyd Foundation Melanoma Research Grant (CY)
Grant: IK6BX005225 (AR)
Lloyd Foundation Melanoma Research Grant (CY)
Grant: 101BX002301 (AR)
National Institutes of Health
Grant: 5IK6BX005225-04
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
National Institutes of Health
Grant: 5R01CA116021-09
Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma
National Institutes of Health
Grant: 5R01CA243326-05
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
FWCI
6.27
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals